New two-year data for Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two causes of vision loss – Genentech/Roche
Genentech, announced that new two-year data from its Phase III studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be… read more.
